Mis416 (DrugBank: -)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 13 | 多発性硬化症／視神経脊髄炎 | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02228213 (ClinicalTrials.gov) | October 2014 | 21/8/2014 | Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis | A Phase 2B Randomised, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of MIS416 in the Treatment of Subjects With Secondary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Biological: MIS416;Drug: Saline | Innate Immunotherapeutics | INC Research | Completed | 18 Years | 70 Years | All | 93 | Phase 2 | Australia;New Zealand |
| 2 | NCT01191996 (ClinicalTrials.gov) | August 2010 | 30/8/2010 | Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis | A Phase 2, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, and Pharmacodynamics of Intravenously Administered MIS416 in Patients With Chronic Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis;Primary Progressive Multiple Sclerosis | Biological: MIS416 | Innate Immunotherapeutics | Primorus Clinical Trials;National Multiple Sclerosis Society | Completed | 18 Years | N/A | Both | 34 | Phase 1;Phase 2 | New Zealand |